About
About Morepen Laboratories Limited
Morepen Laboratories Limited develops, manufactures, markets, and sells active pharmaceutical ingredients (APIs), branded and generic formulations, and home health products in India, the United States, and internationally. The company offers APIs for anti-histaminic, anti-asthmatic, anti-lipemic, anti-hypertensive, anti-diabetic, anti-coagulant, anti-ulcerative, NASH/ MASH treatment products, CKD treatment, and anti-depressant drugs; and home diagnostic and point-of-care medical devices products, such as blood glucose monitor and test strips, blood pressure monitors, respiratory devices, ortho support, digital thermometers, digital weighing scale, fertility, nebulizers, pulse oximeters, vaporizers, orthopaedic, stethoscope, and miscellaneous products. It also provides OTC healthcare products; and formulations for nutrition and probiotics, gastroenterology, antibiotics, gynecology, anti-allergic, and central nervous system, as well as cardiology, diabetology, and nutraceuticals. In addition, the company offers over the counter products under the Dr. Morepen brand name. Morepen Laboratories Limited was incorporated in 1984 and is based in Gurugram, India.
Research context
Morepen Laboratories Limited appears in PyInvesting’s India Stock catalogue. The price history above describes this recorded instrument; it does not by itself identify a company’s business or establish a continuous investment return.
- Currency
- INR
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
These are the latest stored catalogue classifications, not a historical classification snapshot. An issuer description, classification effective date or currency may be unavailable. Check the issuer’s own disclosures and the observation dates before using these fields for research.
Review backtest assumptions and evidence before treating a chart or stored history as a research result.
Visit company website
5 years, 6 months ago
Morepen Laboratories Limited is currently in a long term uptrend where the price is trading 86.0% above its 200 day moving average.
From a valuation standpoint, the stock is 72.8% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 1.3.
Morepen Laboratories Limited's total revenue rose by 33.6% to $3B since the same quarter in the previous year.
Its net income has increased by 120.0% to $238M since the same quarter in the previous year.
Finally, its free cash flow grew by 352.0% to $200M since the same quarter in the previous year.
Based on the above factors, Morepen Laboratories Limited gets an overall score of 5/5.